CCClaudia Haydee Sarai Caro-Sánchez

Claudia Haydee Sarai Caro-Sánchez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claudia Haydee Sarai Caro-Sánchez has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterizing Warthin-Like Mucoepidermoid Carcinoma: Clinicopathologic Features and MAML2 Rearrangements in 14 Latin American Cases

    by Ricardo Anderson de Oliveira Vasconcelos, Isaac Santos Araújo, Luiz Miguel Ferreira, João Paulo Gonçalves de Paiva, Igor Lima Fernandes, Lucas Faria Abrahao-Machado, Claudia Haydee Sarai Caro-Sánchez, Ana María Cano-Valdez, Adalberto Mosqueda-Taylor, Ciro Dantas Soares

    Purpose: Warthin-like mucoepidermoid carcinoma (WL-MEC) is a low-grade variant of mucoepidermoid carcinoma (MEC), characterized by a multicystic growth pattern and dense lymphoid stroma, histologically mimicking Warthin tumor (WT). Few cases have been reported, limiting understanding of this variant. We aimed to provide a comprehensive clinical, histopathologic, and molecular analysis of new WL-MEC cases. Methods and Results: Fourteen WL-MEC cases from Brazil, Guatemala, and Mexico were analyzed. Clinicopathologic features (patient demographics, tumor location, AFIP grading, follow-up, recurrence), histological characteristics (architectural patterns, inflammatory infiltrate, epithelial components, invasion), and immunohistochemical profiles (CK5/6, p63, p40, CK7, CK14, Ki67, HER2) were assessed. MAML2 generearrangements and HER2 amplification were evaluated by fluorescence in situ hybridization (FISH). All 14 cases showed MAML2 rearrangement (100%), confirming the diagnosis, while HER2 amplification was absent in all 9 cases tested. Conclusions: This study provides new insights into the clinicopathological and molecular features of WL-MEC, confirming its typical presentation (parotid gland, middle-aged females), low-grade behavior, and favorable prognosis after surgical excision. Detection of MAML2 rearrangement is a valuable diagnostic tool for distinguishing WL-MEC from WT.

  • Durable response to brigatinib in a ROS1 fusion–positive inflammatory myofibroblastic tumor

    by Gabriela Alamilla-García, Oscar Tahuahua-Flores, Alejandro Soriano-Maya, Enrique Caballé-Pérez, Claudia Haydee Sarai Caro-Sánchez, Dorian Yarih García-Ortega

  • Top Cited Papers

    Clinicopathological Analysis of Salivary Glands Warthin-like Mucoepidermoid Carcinoma: A Systematic Review

    by Ricardo Anderson de Oliveira Vasconcelos, Isaac Santos Araújo, Luiz Miguel Ferreira, João Paulo Gonçalves Paiva, Maíra Medeiros Pacheco de Andrade, Igor Fernandes, Lucas Faria Abrahao-Machado, Claudia Haydee Sarai Caro-Sánchez, Ana Cano Cano-Valdez, Adalberto Mosqueda-Taylor, et al.

    Purpose This systematic review summarizes the current literature on Warthin-like mucoepidermoid carcinoma (WL-MEC), highlighting its clinicopathological, immunohistochemical and molecular characteristics. Methods This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was registered by PROSPERO (protocol CRD42024523598). Case reports and case series published in English on WL-MEC of major and minor salivary glands were included. The search was conducted in MEDLINE/PubMed, Scopus, Web of Science, and Embase databases in November 2024, along with a search in grey literature. Twenty-one articles met the eligibility criteria. The extracted information included clinicopathological data, immunohistochemical and molecular tests, treatment, recurrence, metastasis, follow-up, and status. The data analysis was performed descriptively, and presented as absolute and relative frequencies, and means or median for numerical variables. Results 78 WL-MEC cases were analyzed, with a female predominance observed and a wide age range, peaking in the sixth decade of life. Most cases involved the parotid gland and presented as indolent nodular masses, often asymptomatic. Histologically, the majority were low-grade tumors, with multicystic growth patterns and a lymphocytic infiltrate. Immunohistochemical analysis revealed consistent expression of p63, p40, CK5/6, and exhibited low Ki67 proliferation index (< 5%). MAML2 rearrangement was identified in all molecularly analyzed cases (n = 72/ 100%). Surgical treatment was the most common approach, which typically resulted in low recurrence rates, no distant metastasis, and favorable overall outcomes. Conclusion WL-MEC cases typically present as indolent, asymptomatic nodules in the parotid gland, often with a female predominance and a wide age range, peaking in the sixth decade of life. Surgery is the primary treatment and is associated with a favorable prognosis, characterized by low rates of recurrence and metastasis. These tumors commonly exhibit low-grade histopathological features, a multicystic pattern, and lymphocytic inflammatory infiltrate. The detection of MAML2 rearrangement, typically via FISH, is an essential diagnostic tool, emphasizing the molecular similarities between WL-MEC and conventional MEC.


  • Open Access

    Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer

    by Montserrat Justo-Garrido, Alejandro López-Saavedra, Nicolás Alcaraz, Carlo C. Cortés-González, Luis F. Oñate-Ocaña, Claudia Haydee Sarai Caro-Sánchez, Clementina Castro-Hernández, Cristian Arriaga-Canon, José Díaz-Chávez, Luis A. Herrera

    Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance.


  • Open Access

    Acrometástasis en astrágalo de adenocarcinoma endometrioide

    by Miguel Ángel Clara-Altamirano, Dorian Yarih García-Ortega, Claudia Haydee Sarai Caro-Sánchez, Jorge Luis Martínez-Tlahuel, Héctor Martínez-Said, Mario Cuéllar-Hubbe